Trial Profile

A multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ENX-101 at plasma steady state in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ENX-101 (Primary)
Indications Neurological disorders
Focus Adverse reactions
Acronyms ENX-101
Sponsors Engrail Therapeutics

Most Recent Events

07 Jun 2022 According to an Engrail Therapeutics media release, data from this study were presented on June 6, 2022, at the 2022 Epilepsy Pipeline Conference in Santa Clara, California.
07 Jun 2022 Status changed from planning to completed , according to Engrail Therapeutics media release.
07 Jun 2022 Results presented in an Engrail Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com